Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).
Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with diet-induced MASH.
Daiichi Sankyo Co. Ltd. and Astrazeneca plc have submitted a new BLA to the U.S. FDA for accelerated approval for datopotamab deruxtecan for treating locally advanced or metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer patients who have received prior systemic therapies.
Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to license the therapy for further development and commercialization, resulting in a milestone payment to Quell of $10 million.
Daiichi Sankyo Co. Ltd. and Astrazeneca plc have submitted a new BLA to the U.S. FDA for accelerated approval for datopotamab deruxtecan for treating locally advanced or metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer patients who have received prior systemic therapies.
Alteogen Inc. scored another deal for its human recombinant enzyme, ALT-B4, on Nov. 8, reeling in Daiichi Sankyo Co. Ltd. in a potential $300 million deal including $20 million up front and up to $280 million in milestone payments, along with royalties based on net sales.
Alteogen Inc. scored another deal for its human recombinant enzyme, ALT-B4, on Nov. 8, reeling in Daiichi Sankyo Co. Ltd. in a potential $300 million deal including $20 million up front and up to $280 million in milestone payments, along with royalties based on net sales.
In a pipeline shakeup, Tango Therapeutics Inc. has halted enrollment in a phase I/II study in order to push two other brain cancer drugs into development. TNG-908 had success in treating non-CNS solid tumors such as non-small-cell lung cancer and pancreatic cancer but missed the minimum pharmacokinetic exposure in clinical efficacy for treating glioblastoma.
Astrazeneca plc’s China president, Leon Wang, is under investigation in mainland China, the company said in an Oct. 30 statement. Although details are scant, Astrazeneca said Wang is “cooperating with an ongoing investigation by Chinese authorities,” and the company’s China operations will continue under the leadership of the current general manager of Astrazeneca China.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease characterized by the inflammation of blood vessels, and it has been demonstrated that myeloperoxidase (MPO) is one of the major disease drivers of AAV, as it is a neutrophil surface protein that binds to ANCA.
